Loading...
Market
What will be the market adoption level of ANX005 by mid-2025?
5
Resolution / Starting Odds
High market adoption • 33%
Moderate market adoption • 33%
Low market adoption • 33%
Market research reports and sales data
Story
Annexon Biosciences' ANX005 Meets Phase 3 Endpoint in GBS, Shares Surge Over 55%
Jun 4, 2024, 11:30 AM
Annexon Biosciences announced that its experimental drug, ANX005, met the primary endpoint in a Phase 3 trial for treating Guillain-Barré Syndrome (GBS). The trial showed a highly statistically significant 2.4-fold improvement in the GBS-DS endpoint at 8 weeks with a 30 mg/kg dose, compared to placebo (p=0.0058). However, the 75 mg/kg dose did not show statistical significance (p=0.5548). Following the announcement, Annexon's shares surged more than 31% before the bell, were up 55% in pre-market trading, and rose 48.0% pre-market. The company will discuss the Phase 3 data in a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET.
View original story
Similar markets
High adoption (Above 30%) • 33%
Moderate adoption (15-30%) • 33%
Low adoption (Below 15%) • 34%
Low adoption • 33%
Moderate adoption • 34%
High adoption • 33%
Low penetration (<1%) • 25%
Moderate penetration (1-3%) • 25%
High penetration (3-5%) • 25%
Very high penetration (>5%) • 25%
Increase in adoption • 33%
No change • 33%
Decrease in adoption • 34%
Widely adopted in media • 33%
Widely adopted in entertainment • 33%
Limited adoption • 34%
Widely adopted in tech industry • 33%
Limited adoption to specific sectors • 33%
Minimal adoption • 34%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%